Loading clinical trials...

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL) | Clinical Trials | Clareo Health

UNKNOWNNANCT04933825

A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

The purpose of this study is to evaluate the safety and efficacy of CD19-UCART in patients with r/r B-cell hematological malignancies.

Lead sponsor: EdiGene (GuangZhou) Inc.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment18

Start dateJul 2021

Last updatedFeb 17, 2023

Condition

Relapsed or Refractory B-cell Malignancy(NHL/ALL)

Locations shown

•The First Affiliated Hospital of Henan University of Science and Technology

Luoyang, Henan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2023Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions